由於其個人的幻覺體驗,舒爾金的研究重心仍傾斜於精神藥學,但在此期間他無法做太多的自主研究。由於舒爾金發明了第一種可生物降解(biodegradable)的氨基甲酸酯類殺蟲劑茲克威(英语:Mexacarbate),陶氏為回報這一潛在利潤極高的專利而予以他極大的自主性,令其得以進行更進一步的研究。 在此期間,舒爾金應陶氏要求發明了一系列專利藥物,並將他在其他藥物上的發現發表於自然(Nature)、有機化學期刊(Journal of Organic Chemistry)等刊物中。最終,陶氏要求舒爾金不得再以公司名義出版其作品[7]。
1966年底,為了追求自己的興趣,舒爾金從陶氏化學辭職。在加州大学旧金山分校医學院,舒爾金為一個諮詢項目工作了兩年兼修讀神經內科。他在其所擁有的土地上籌建了一個家庭實驗室(home-based lab)(即“農場”),並成為了一名私人顧問。與此同時,舒爾金還為當地大學及舊金山總醫院(San Francisco General Hospital)授課。通過美国缉毒局 (DEA) 西部實驗室主管Bob Sager的引薦,舒爾金與DEA建立了聯繫,開始為DEA特工召開藥理學講座、向DEA提供各種化合物之樣品,偶爾也作為見證專家出席法庭。1988年,舒爾金針對管制藥物出版了一本簡明的執法參考用書[9],並因此獲得DEA所頒發的數個獎項[7]
。
1964. with H. O. Kerlinger. "Isolation of methoxyeugenol and trans-isoelemicin from oil of nutmeg". Naturwissenschaften 15: 360-361. 31
1965. "Synthesis of the trimethoxyphenylpropenes". Can. J. Chem. 43: 3437-3440. 43
1966. "Possible implication of myristicin as a psychotropic substance". Nature 210: 380-384. 45
1966. "The six trimethoxyphenylisopropylamines (trimethoxyamphetamines)". J. Med. Chem. 9: 445-446. 46
1966. with T. Sargent, and C. Naranjo. "Role of 3,4-Dimethoxyphenethylamine in schizophrenia". Nature 212: 1606-1607. 48[17]
1967. with T. Sargent, and C. Naranjo. "The chemistry and psychopharmacology of nutmeg and of several related phenylisopropylamines". In D. H. Efron [ed.]: Ethnopharmacologic search for psychoactive drugs. U. S. Dept. of H. E. W., Public Health Service Publication No. 1645. Pp. 202–214. Discussion: ibid. pp. 223–229. 49
1967. with T. Sargent. "Psychotropic phenylisopropylamines derived from apiole and dillapiole". Nature 215: 1494-1495. 50
1967. with Sargent, T. W., D. M. Israelstam, S. A. Landaw, and N. N. Finley. "A note concerning the fate of the 4-methoxyl group in 3,4-dimethoxyphenethylamine (DMPEA)". Biochem. Biophys. Res. Commun. 29: 126-130. 52
1967. with Naranjo, C. and T. Sargent. "Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy". Med. Pharmacol. Exp. 17: 359-364. 53
1968. "The ethyl homologs of 2,4,5-trimethoxyphenylisopropylamine". J. Med. Chem. 11: 186-187. 54
1969. with T. Sargent and C. Naranjo. "Structure activity relationships of one-ring psychotomimetics". Nature 221: 537-541. 57
1969. "Recent developments in cannabis chemistry". J. Psyched. Drugs 2: 15-29. 58
1969. "Psychotomimetic agents related to the catecholamines". J. Psyched. Drugs 2(2): 12-26. 59
1970. "Chemistry and structure-activity relationships of the psychotomimetics". In D. H. Efron [ed.]. "Psychotomimetic Drugs". Raven Press, New York. Pp. 21–41. 60
1970. "The mode of action of psychotomimetic drugs; some qualitative properties of the psychotomimetics". Neur. Res. Prog. Bull. 8: 72-78. 61
1970. "4-alkyl-dialkoxy-alpha-methyl-phenethylamines and their pharmacologically-acceptable salts". U. S. Patent 3,547,999, issued Dec. 15, 1970. 63
1971. with T. Sargent and C. Naranjo. "4-bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog". Pharmacology 5: 103-107. 64
1971. "Chemistry and sources". In S. S. Epstein [ed]. "Drugs of abuse: their genetic and other chronic nonpsychiatric hazards". The MIT Press, Cambridge, Mass. Pp 3–26. 65
1971. "Preliminary studies of the synthesis of nitrogen analogs of Delta1-THC". Acta Pharm. Suec. 8: 680-681. 66
1972. "Hallucinogens, CNS stimulants, and cannabis. In S. J. Mulé and H. Brill [eds.]: Chemical and biological aspects of drug dependence". CRC Press, Cleveland, Ohio. Pp. 163–175. 67
1973. "Stereospecific requirements for hallucinogenesis". J. Pharm. Pharmac. 25: 271-272. 68
1973. "Mescaline: the chemistry and pharmacology of its analogs". Lloydia 36: 46-58. 69
1973. "The narcotic pepper - the chemistry and pharmacology of Piper methysticum and related species". Bull. Narc. 25: 59-1974. "Le poivre stupéfiant - chemie et pharmacologie du Piper methysticum et des espéces apparentées". Bull. Stupéfiants 25: 61-77. 70
1973. with T. Sargent and C. Naranjo. "Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenylisopropylamine (MMDA)". Pharmacology 10: 12-18. 71
1974. with Kalbhen, D. A., T. Sargent, G. Braun, H. Stauffer, N. Kusubov, and M. L. Nohr. "Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxyphenylisopropylamine labelled with [82]Br". IRCS (Int. Res. Comm. Sys.) 2: 1091. 73
1975. with Sargent, T., D. A. Kalbhen, H. Stauffer, and N. Kusubov. "A potential new brain-scanning agent: 4-[77]Br-2,5-dimethoxyphenylisopropylamine (4-Br-DPIA)". J. Nucl. Med. 16: 243-245. 74
1975. with M. F. Carter. "Centrally active phenethylamines". Psychopharm. Commun. 1: 93-98. 75
1975. with Sargent, T., D. A. Kalbhen, G. Braun, H. Stauffer, and N. Kusubov. "In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with [82]Br or [77]Br". Neuropharmacology 14: 165-174. 76
1975. "The chemical catalysis of altered states of consciousness. Altered states of consciousness, current views and research problems". The drug abuse council, Washington, D. C. Pp. 123–134. 77
1975. "Drug use and anti-drug legislation". The PharmChem Newsletter 4 (#8). 79
1975. with D. C. Dyer. "Psychotomimetic phenylisopropylamines. 5. 4-alkyl-2,5-dimethoxyphenylisopropylamines". J. Med. Chem. 18: 1201-1204. 80
1975. with C. Helisten. "Differentiation of PCP, TCP, and a contaminating precursor PCC, by thin layer chromatography". Microgram 8: 171-172. 81
1975. with Helisten, C. "The detection of 1-piperidinodydlohexanecarbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl)piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine". J. Chrom. 117: 232-235. 82
1976. "Psychotomimetic agents". In M. Gordon [ed.] "Psychopharmacological agents", Vol. 4. Academic Press, New York. Pp. 59–146. 83
1976. "Abuse of the term 'amphetamines'". Clin. Tox. 9: 351-352. 84
1976. "Profiles of psychedelic drugs. 1. DMT". J. Psychedelic Drugs 8: 167-168. 85
1976. "Profiles of psychedelic drugs. 2. TMA-2". J. Psychedelic Drugs 8: 169. 86
1976. with D. E. MacLean. "Illicit synthesis of phencyclidine (PCP) and several of its analogs". Clin. Tox. 9: 553-560. 87
1976. with Nichols, D. E. "Sulfur analogs of psychotomimetic amines". J. Pharm. Sci. 65: 1554-1556. 89
1976. with Sargent, T. and N. Kusubov. "Quantitative measurement of demethylation of [14]C-methoxyl labeled DMPEA and TMA-2 in rats". Psychopharm. Commun. 2: 199-206. 90
1976. with Standridge, R. T., H. G. Howell, J. A. Gylys, R. A. Partyka. "Phenylalkylamines with potential psychotherapeutic utility. 1. 2-amino-1-(2,5,-dimethoxy-4-methylphenyl)butane". J. Med. Chem. 19: 1400-1404. 91
1976. "Profiles of psychedelic drugs. 3. MMDA". J. Psychedelic Drugs 8: 331. 92
1977. "Profiles of psychedelic drugs. 4. Harmaline". J. Psychedelic Drugs 9: 79-80. 93
1977. "Profiles of psychedelic drugs. 5. STP". J. Psychedelic Drugs 9: 171-172. 94
1977. with Nichols, D. E., and D. C. Dyer. "Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives". Life Sciences 21: 569-576. 95
1977. with Jacob, P. III, G. Anderson III, C. K. Meshul, and N. Castagnoli Jr. "Mononethylthio analogues of 1-(2,4,5-trimethoxyphenyl)2-aminopropane". J. Med. Chem. 20: 1235-1239. 96
^Ancestry.com. California Birth Index, 1905-1995 [database on-line]. Provo, UT, USA: Ancestry.com Operations Inc, 2005. Original data: State of California. California Birth Index, 1905-1995. Sacramento, CA, USA: State of California Department of Health Services, Center for Health Statistics.
^Ancestry.com. California Death Index, 1940-1997 [database on-line]. Provo, UT, USA: Ancestry.com Operations Inc, 2000. Original data: State of California. California Death Index, 1940–1997. Sacramento, CA, USA: State of California Department of Health Services, Center for Health Statistics.
^Ancestry.com. California Death Index, 1940–1997 [database on-line]. Provo, UT, USA: Ancestry.com Operations Inc, 2000. Original data: State of California. California Death Index, 1940–1997. Sacramento, CA, USA: State of California Department of Health Services, Center for Health Statistics.